Mesothelioma Help Cancer News
Mesothelioma Patients Should Heed FDA Warnings Regarding Miracle Cures
In pursuit of its mission to protect the public health by ensuring the safety and efficacy of drugs, the U.S. Food and Drug Administration sent out warning letters to 14 companies claiming their products can prevent, diagnose, treat or cure cancer. The products, none of which have been approved by the FDA, can be appealing to mesothelioma patients or anyone fighting a terminal cancer, but they could lead to severe illness or, potentially, death.
In each of the 14 letters, found on the FDA’s website, the Agency notes that the items being marketed fall under the Federal Food, Drug, and Cosmetic Act due to the intended use in the cure, mitigation, treatment, or prevention of disease. The letters go on to itemize examples of the claims on the company’s website, product label, social media and other media that provide evidence the products are intended for use as drugs.
It is a violation of federal law to market and sell products that claim to prevent, diagnose, treat, mitigate or cure diseases without first demonstrating to the FDA that they are safe and effective for their labeled uses.
Among the 65 products the FDA cited are claims for a tea with “cancer killing properties”; a vitamin that can “stop cancer cells from multiplying, kill cancer cells, and block their blood supply”; and drugs that are a “chemopreventive agent due to their ability to modulate underlying mechanisms involved in carcinogenesis.”
“Consumers should not use these or similar unproven products because they may be unsafe and could prevent a person from seeking an appropriate and potentially life-saving cancer diagnosis or treatment,” said Douglas W. Stearn, director of the Office of Enforcement and Import Operations in the FDA’s Office of Regulatory Affairs, in the April 25 press release announcing the warnings.
Although there are the rare cases of individuals who have survived mesothelioma through holistic care, the saying “it takes a village” is applicable to the fight against mesothelioma. A mesothelioma care team may include the family physician, a medical oncologist, pulmonologist, surgeon, radiologist, nurses, pathologists, nutritionists, rehab therapists and social workers.
Mesothelioma is caused by the inhalation or ingestion of airborne asbestos fibers. In the case of pleural mesothelioma, the fibers lodge deep in tissue surrounding the lungs, causing inflammation that festers for years. Chronic, persistent inflammation is a known cause of cancer, and in the case of mesothelioma, can take decades to develop into a malignancy. Mesothelioma is deemed an incurable cancer, with an estimated survival of less than 18 months after diagnosis.
Many mesothelioma patients turn to holistic treatments as complementary treatments to help relieve symptoms and to ease stress, but anytime a company makes a claim that its product can cure cancer, you can be sure the claim is fraudulent.
“We encourage people to remain vigilant whether online or in a store, and avoid purchasing products marketed to treat cancer without any proof they will work,” said Stearn. “Patients should consult a health care professional about proper prevention, diagnosis and treatment of cancer.”
The companies have 15 days from receipt of the letter to respond to the FDA with information regarding the actions they have taken to correct the violations and to assure violations do not happen again. According to the FDA, failure to correct the violations promptly may result in legal action, including product seizure, injunction and/or criminal prosecution.
Remembering Loved Ones Lost to Mesothelioma
Each spring a Memorial Service is held for families that have lost loved ones to mesothelioma. It never gets any easier to see the personal toll that this deadly cancer has taken. Remembering patients and families that have dealt with the death of a loved one from mesothelioma is sobering. Every year a member of the mesothelioma medical team talks about the progress that continues to be made toward a cure. Although not fast enough for these families and loved ones, the update always helps everyone in attendance, by offering hope. Hope that no other patients and families will have to go through what they have been through and suffer the losses that they have.
The service is a testimony to the generosity of the human spirit. Although their loved ones are gone, the families and loved ones are their representatives on earth. By putting a face to the patient, and showing the whole picture of the victims of this disease, researchers can take this snapshot of their relatives back to the lab with them for inspiration in the coming year. Each year there is progress to report and each year there is appreciation for the continuous support of these brave families, and continued support of the work needed for a cure.
There is a lot of ambivalence about attending a memorial service like this. From our experiences over the years, when the service is over families feel better. By acknowledgment that their loved one’s fight is over, and that they have potentially helped other patients in the future, does provide some comfort for the families. For some it is difficult to come back to a place that holds painful memories.
One family member acknowledging that she almost did not come, spoke of coming back to a place that had offered her and her family hope when they could not find it anywhere else. Although her family member had died, she was grateful for the quality time they did have together.
The reasons for attending are as varied as the patients. Stories and memories are shared,and a grateful community leans on each other to continue on to a day when there will be no need for an annual Memorial Service for mesothelioma patients.
Mesothelioma Patients Can See Improved Survival By Reporting Side Effects
Chemotherapy and other treatments for mesothelioma can lead to debilitating side effects such as pain, nausea and fatigue. But patients often suffer in silence with their symptoms which, when left untreated, can lead to severe complications, and even death. Now, researchers say it does not need to be that way, and, in fact, by opening up to their physicians, patients can improve their quality of life and their survival.
Researchers from Memorial Sloan Kettering Cancer Center followed 766 advanced cancer patients undergoing care at the Center, according to a June 4 report from ABC News (https://abcnews.go.com/Politics/wireStory/emergency-bill-fund-veterans-affairs-department-32742493). Hoping to catch issues before they became severe, researchers gave some of the patients access to an online tool to report to their medical team weekly, or more often if they experienced unusual or severe symptoms. The patients self-reported information on 12 common symptoms including appetite loss, diarrhea, shortness of breath, fatigue and pain.
After just six months, the patients in the online reporting group had an improved health-related quality of life and fewer trips to the emergency room. In addition, overall, they stuck with the chemotherapy treatment two months longer, eight months as opposed to six months in the non-online group.
Surprising even the researchers, median survival of the patients in the online group was nearly six months longer at 31 months versus 26 months for the control group. Researchers believe the survival was tied to early responsiveness to patients’ symptoms that prevented “adverse downstream consequences” and increased tolerance to chemotherapy allowing them to continue on the treatment beyond usual care.
“I was floored by the results,” said the study lead, Dr. Ethan Basch, a researcher at the University of North Carolina-Chapel Hill and Memorial Sloan Kettering Cancer Center in New York. “We are proactively catching things early.”
When a patient reported a concerning health issue, a nurse responded immediately almost 80 percent of the time. They would get the patient prescription medications, or appropriate care, to handle their specific issues. The tool gave the patients an easy way to report issues without struggling to get through to their doctor or wait for their next appointment.
The researchers concluded, “Electronic patient-reported symptom monitoring may be considered for implementation as a part of high-quality cancer care.” They now plan to launch a larger study to test the online reporting system nationwide.
Mesothelioma is diagnosed in approximately 3,000 Americans each year. Although treatments increase survival, countless mesothelioma patients have said the treatment is worse than the disease. That is not necessarily the case, and patients should not hesitate to reach out to their medical team to help alleviate some of their side effects.
Results of the study were presented at the 2017 ASCO Annual Meeting in Chicago. Find the full study in the June 4 issue of Journal of the American Medical Association (http://jamanetwork.com/journals/jama/fullarticle/2630810).
Mesothelioma Patients May Have Another Treatment Option With FDA Expanded-Use Approval of Lung Cancer Drug
In September, MesotheliomaHelp reported that Italian researchers found the response to ceritinib (Zykadia), an anti-cancer drug, was nearly immediate in non-small cell lung cancer patients who were previously treated with chemotherapy and crizotinib (Xalkori). Now, the U.S. Food and Drug Administration has granted approval for expanded use of the drug to include the first-line treatment of NSCLC patients with ALK-positive tumors, opening the door for another treatment option for mesothelioma patients.
Ceritinib, marketed as Zykadia by Novartis, is intended for the treatment of metastatic NSCLC in patients who express the abnormal anaplastic lymphoma kinase (ALK) gene. Approximately 3%-5% of people with NSCLC may test positive for the ALK fusion gene. There is a potential that the marker is also present in certain pleural mesothelioma cases making it a new treatment option for the cancer.
In a May 26 press release from Novartis, the company reports that of the 376 patients in the study, those receiving Zykadia as first-line treatment realized a 16.6 month progression-free survival versus 8.1 months in patients treated with pemetrexed-platinum chemotherapy first-line regimen.
“Today’s approval represents the next step in the development of Zykadia as a treatment option for ALK-positive metastatic NSCLC, bringing this important medication to a patient population where a need still exists,” said Bruno Strigini, CEO, Novartis Oncology.
Pleural mesothelioma patients and oncologists keep a close eye on research and breakthroughs that impact NSCLC patients. Although the two cancers have some differences, including the structure of the tumors, patients often follow a similar treatment protocol.
“At Novartis, we are tireless in our pursuit of developing novel medicines to treat lung cancer, and the first-line approval of Zykadia for ALK-positive metastatic NSCLC illustrates our commitment to cancer patients,” said Strigini.
Close to 3,000 patients are diagnosed with mesothelioma each year in the U.S. Although survival has improved in recent years, there is still no cure for the asbestos-caused cancer.
To find out if you may be a candidate for Zykadia, talk to your medical professional. Visit the Novartis website for more information.
Resilience Can Help Patients & Families Come Back Stronger
In life, things can happen that shake us up and change the way we look at the world. Trauma, accidents, crimes against us or an unexpected diagnosis of mesothelioma for you or a family member, for example, can change your world in minutes. It is said that how we respond to these events is what makes us stronger. Through these events we often hear the word resilience talked about. What exactly does that mean?
According to Psychology Today, resilience “is that ineffable quality that allows some people to be knocked down by life and come back stronger than ever. Rather than letting failure overcome them and drain their resolve, they find a way to rise from the ashes.”
In the book, “Option B Facing Adversity, Building Resilience, and Finding Joy,” by Sheryl Sandberg and Adam Grant, resilience, grief, and moving forward, are explored. Ms. Sandberg’s sudden loss of her husband and her coping with her young children’s grief, as well as her own, is documented. In collaboration with Adam Grant, a psychologist and professor at Wharton, who has studied how people find motivation and meaning, Sheryl tells her story. Adam fills in the research on dealing with these issues.
This is an excellent book, easy to read, and is bound to help you at some point in your life. One of the interesting takeaways from the book is that, “more than half of the people who experience a traumatic event report at least one positive change, compared to less than 15% who develop PTSD.” The authors say, “If you don’t see if growth is possible, you’re not going to find it.”
With malignant mesothelioma, unfortunately, loss happens. Everyone’s life and circumstances are different, “Option B” is just one person’s story. We all have our own stories, but it is reassuring to know that others who have endured loss are eventually able to experience joy again. We are not alone as we journey through our lives adventures and challenges.
Free Mesothelioma Patient & Treatment Guide
We’d like to offer you our in-depth guide, “A Patient’s Guide to Mesothelioma,” absolutely free of charge.
It contains a wealth of information and resources to help you better understand the condition, choose (and afford) appropriate treatment, and exercise your legal right to compensation.
Download Now